Dr Anna Sureda, President of the European Society for Blood and Marrow Transplantation (EBMT), shares updates from the HARMONY Alliance, a partnership of more than 100 European organizations such as hospitals, research institutes, patient organizations, pharmaceutical companies, regulatory agencies, IT companies and medical associations such as EBMT and EHA. The joint mission is to accelerate the development of more effective treatments for patients with haematological malignancies. The Big Data Platform is fully equipped to facilitate state-of-the-art research into these malignancies.
Disclosures: Anna Sureda has received honoraria from Alexion, Amgen, BMS/Celgene, Gilead Kite, Janssen, MSD, Novartis, Roche, Sanofi and Takeda, and consultancy fees from BMS/Celgene, Gilead, Janssen, Novartis, Sanofi and Takeda. She is on the speaker’s bureau for and has received research support from Takeda. Non-profit organizations roles include Presidency of the EBMT and presidency of the GETH-TC.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
